Michael Monostra is an Online Content Editor at Healio and MONTCO.Today. He focuses on themes related to medicine and healthcare, with particular emphasis on healthcare technology, digital health, endocrinology, telehealth, and prenatal care. His work has been featured in notable publications, including Healio and MONTCO.Today.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Michael Monostra's coverage mainly focuses on medical research, diabetes, obesity, thyroid disease, and hormone therapy. He predominantly cites data in his articles. To effectively reach out to Michael, consider providing him with new and significant scientific findings or studies related to these topics. Make sure to offer access to credible experts who can provide insightful commentary on the latest research developments in healthcare and pharmaceuticals.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Michael Monostra, Richard Smith
CHICAGO — Most adults receiving a once-weekly hypoparathyroidism therapy were able to maintain normal calcium levels at 12 weeks without active vitamin D and oral calcium supplementation, according to data from a phase 2 trial.
By: Michael Monostra, Richard Smith
CHICAGO — Burosumab is tied to greater improvements in pain, stiffness and physical function than active vitamin D and phosphate salts among patients with X-linked hypophosphatemia, according to data presented at ENDO 2026.
By: Richard Smith, Michael Monostra
The American Diabetes Association issued a video statement and apology from the CEO on June 10, after five attendees were removed from its annual Scientific Sessions.
By: Katie Kalvaitis, Michael Monostra, Richard Smith
NEW ORLEANS —Adults with type 2 diabetes receiving once-daily orforglipron alongside insulin glargine had greater improvements in HbA1c than those receiving placebo, according to data from the ACHIEVE-5 trial.
By: Richard Smith, Michael Monostra, Katie Kalvaitis
NEW ORLEANS — Once-daily orforglipron induced greater reductions in HbA1c than dapagliflozin and oral semaglutide for adults with type 2 diabetes, according to findings from the ACHIEVE-2 and ACHIEVE-3 trials.
By: Richard Smith, Michael Monostra
CHICAGO — Adults with type 2 diabetes may have lower risk for fractures if they use semaglutide compared with other medications, according to data presented at ENDO 2026.
By: Michael Monostra, Richard Smith
CHICAGO — Osilodrostat conferred a broad range of quality of life improvements for people with Cushing's disease in two trials, researchers reported.
By: Richard Smith, Michael Monostra
PHILADELPHIA — Using a GLP-1 receptor agonist in combination with an SGLT2 inhibitor may provide additive cardiovascular and renal benefits for
By: Richard Smith, Michael Monostra
NEW ORLEANS — Fewer than half of children and adolescents with type 2 diabetes are prescribed GLP-1 receptor agonists at most pediatric diabetes
By: Richard Smith, Michael Monostra
PHILADELPHIA — Health care professionals should use the full spectrum of continuous glucose monitoring metrics to assess complication risk for people with diabetes, according to a speaker at the Heart in Diabetes CME Conference.
